High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine

Journal of Clinical Immunology

Volumn 34, Issue 6, 2014, Pages 655-662

  Yam, Karen K ^a   Gipson, Erica ^a   Klein, Marina ^b   Walmsley, Sharon ^c   Haase, David ^d   Halperin, Scott ^d   Scheifele, David ^e   Ward, Brian J ^a   Cooper, Curtis ^f  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Adjuvant; antibody avidity; HIV; influenza; vaccine

Indexed keywords

ALPHA TOCOPHEROL; ASO3B ADJUVANT; DRUG COMBINATION; INFLUENZA VACCINE; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ADULT; ANTIBODY AFFINITY; BLOOD; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS; MALE; MASS IMMUNIZATION; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; DRUG COMBINATIONS; FEMALE; HIV; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MASS VACCINATION; MIDDLE AGED; POLYSORBATES; SQUALENE; TREATMENT OUTCOME;

EID: 84939885947     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-014-0054-z     Document Type: Article

References (45)

1. Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001;32:1784–91.
2. Radwan HM, Cheeseman SH, Lai KK, Ellison III RT. Influenza in human immunodeficiency virus-infected patients during the 1997–1998 influenza season. Clin Infect Dis. 2000;31:604–6.
3. Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest. 1990;98:33–7.
4. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine. 2002;20 Suppl 5:B29–32.
5. Malaspina A, Moir S, Orsega SM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis. 2005;191:1442–50.
6. Ragni MV, Ruben FL, Winkelstein A, Spero JA, Bontempo FA, Lewis JH. Antibody responses to immunization of patients with hemophilia with and without evidence of human immunodeficiency virus (human T-lymphotropic virus type III) infection. J Lab Clin Med. 1987;109:545–9.
7. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med. 1987;316:673–6.
8. Madhi SA, Dittmer S, Kuwanda L, et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. AIDS. 2013;27:369–79.
9. Labriola L, Hombrouck A, Marechal C, et al. Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. Nephrol Dial Transplant. 2011;26:1424–8.
10. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011;52:248–56.
11. McElhaney JE, Beran J, Devaster JM, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis. 2013;13:485–96.
12. Cooper C, Klein M, Walmsley S, et al. High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials. 2012;13:23–32.
13. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol. 2005;23:487–513.
14. Yam KK, Gupta J, Brewer A, Scheifele DW, Halperin S, Ward BJ. Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine. Clin Vaccine Immunol. 2013;20:459–67.
15. Banzhoff A, Gasparini R, Laghi-Pasini F, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4:e4384.
16. Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011;52:122–7.
17. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis. 2011;52:138–46.
18. Durando P, Fenoglio D, Boschini A, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol. 2008;15:253–9.
19. Ho J, Moir S, Wang W, et al. Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS. 2011;25:295–302.
20. Kajaste-Rudnitski A, Galli L, Nozza S, et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS. 2011;25:177–83.
21. Orlando G, Pariani E, Mazza F, et al. Pandemic influenza vaccine in adult HIV-1-infected patients. AIDS. 2010;24:2142–3.
22. Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One. 2011;6:e16496.
23. Beck JM, Rosen MJ, Peavy HH. Pulmonary complications of HIV infection. Report of the Fourth NHLBI Workshop. Am J Respir Crit Care Med. 2001;164:2120–6.
24. Durier C, Desaint C, Lucht F, et al. Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults. AIDS. 2013;27:87–93.
25. Nielsen AB, Nielsen HS, Nielsen L, Thybo S, Kronborg G. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. Vaccine. 2012;30:7067–71.
26. Tremblay CL, Rouleau D, Fortin C, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine. 2011;29:1359–63.
27. Ferguson M, Risi G, Davis M, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis. 2012;205:733–44.
28. Ikematsu H, Nagai H, Kawashima M, et al. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Hum Vaccin Immunother. 2012;8:260–6.
29. Cooper CL. Pandemic H1N12009 influenza and HIV: a review of natural history, management and vaccine immunogenicity. Curr Opin Infect Dis. 2012;25:26–35.
30. Asner S, Peci A, Marchand-Austin A, et al. Respiratory viral infections in institutions from late stage of the first and second waves of pandemic influenza A (H1N1) 2009, Ontario, Canada. Influenza Other Respir Viruses. 2012;6:e11–5.
31. Labrosse B, Tourdjman M, Porcher R, et al. Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 influenza viruses using a pseudotype neutralization assay. PLoS One. 2010;5:e11036.
32. Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respir Viruses. 2013;7:872–86.
33. Villard O, Breit L, Cimon B, et al. Comparison of four commercially available avidity tests for Toxoplasma gondii-specific IgG antibodies. Clin Vaccine Immunol. 2013;20:197–204.
34. Dollard SC, Staras SA, Amin MM, Schmid DS, Cannon MJ. National prevalence estimates for cytomegalovirus IgM and IgG avidity and association between high IgM antibody titer and low IgG avidity. Clin Vaccine Immunol. 2011;18:1895–9.
35. Fox JL, Hazell SL, Tobler LH, Busch MP. Immunoglobulin G avidity in differentiation between early and late antibody responses to West Nile virus. Clin Vaccine Immunol. 2006;13:33–6.
36. Mercader S, Garcia P, Bellini WJ. Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings. Clin Vaccine Immunol. 2012;19:1810–7.
37. Park DW, Nam MH, Kim JY, et al. Mumps outbreak in a highly vaccinated school population: assessment of secondary vaccine failure using IgG avidity measurements. Vaccine. 2007;25:4665–70.
38. Sanz-Moreno JC, Limia-Sanchez A, Garcia-Comas L, et al. Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G. Vaccine. 2005;23:4921–5.
39. Hazell SL. Clinical utility of avidity assays. Expert Opin Med Diagn. 2007;1:511–9.
40. Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis. 2009;48:1402–12.
41. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000;18:3040–9.
42. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995;182:1727–37.
43. Klein MB, Lu Y, DelBalso L, Cote S, Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis. 2007;45:234–40.
44. Kelly D, Burt K, Missaghi B, et al. Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals. BMC Immunol. 2012;13:49.
45. Calmy A, Bel M, Nguyen A, et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med. 2012;13:207–18.